Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Activus Pharma Co. Ltd.

Division of Sosei Heptares

Latest From Activus Pharma Co. Ltd.

Sosei investigates oral nanoparticle formulations in new Japanese alliance

Sosei has signalled its continuing interest in drug delivery technology through a tie-up with a Japanese venture to conduct joint research into nanoparticle formulations.


2011 Scrip Asia 100 - M&A Watch Asia

M&A Watch: Selected Asian M&A deals, March 2010 to March 2011


Sosei gains Japanese rights to BioAlliance's buccal miconazole

Sosei has paid $3 million up front for Japanese rights to BioAlliance Pharma's adhesive mucobuccal tablet formulation of miconazole, which it will develop and commercialise for oropharyngeal candidiasis in immunocompromised patients.

Metabolic Disorders Infectious Diseases

Sosei to acquire Japanese drug delivery venture

Sosei is to acquire Activus Pharma, a small Japanese venture specialising in nanoparticle-based drug formulations, for a cash consideration of around ¥500 million ($5.5 million).

Respiratory Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Sosei Heptares
  • Senior Management
  • Contact Info
  • Activus Pharma Co. Ltd.
    Venture Plaza Funabashi 218